Integrilin Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Correction to: Delayed-onset eptifibatide-induced thrombocytopenia
Am J Health Syst Pharm. 2024 Apr 16:zxae074. doi: 10.1093/ajhp/zxae074. Online ahead of print.NO ABSTRACTPMID:38624041 | DOI:10.1093/ajhp/zxae074 (Source: American Journal of Health-System Pharmacy : AJHP)
Source: American Journal of Health-System Pharmacy : AJHP - April 16, 2024 Category: Drugs & Pharmacology Source Type: research

A woman with eptifibatide (integrilin) ‐induced thrombocytopenia following treatment of a clot in her coronary artery: A case report and literature review
AbstractEptifibatide, a GPIIb/IIIa receptor inhibitor, has shown its efficacy and safety in patients with high clot burden in their coronary vessels. It is widely used in patients with this condition. However, this medication use is accompanied by complications in some cases. Thrombocytopenia which is a relatively common condition in patients admitted to the hospital, especially in the acute setting, can be caused by medications. This condition can occur as an antibody or non-antibody-mediated process, caused by medications, such as heparin, clopidogrel, and eptifibatide. In this case, we present a woman with acute coronar...
Source: Clinical Case Reports - March 28, 2024 Category: General Medicine Authors: Morteza Safi, Roozbeh Nazari, Nahid Senobari, Homa Taheri, Pouya Ebrahimi Tags: CASE REPORT Source Type: research

An Updated Comprehensive Pharmacovigilance Study of Drug-Induced Thrombocytopenia based on FDA Adverse Event Reporting System Data
This article is protected by copyright. All rights reserved.PMID:38041205 | DOI:10.1002/jcph.2389 (Source: The Journal of Clinical Pharmacology)
Source: The Journal of Clinical Pharmacology - December 2, 2023 Category: Drugs & Pharmacology Authors: Li Kunyu Shi Shuping Su Chang Cao Yiyue Xiong Qinyu Zhang Ting Wu Bin Source Type: research

EPH57 The Market Dynamics of GP IIb/IIIa Inhibitors in Germany: A Closer Look at Eptifibatide and Aggrastat
GP IIb/IIIa inhibitors are widely used antiplatelet drugs used in patients with acute coronary syndrome, undergoing percutaneous coronary intervention (PCI). Prior to 2015, these inhibitors held significant market value, as they were available only in branded forms. However, during the period under review, the patent for eptifibatide and aggrastat expired, leading to the entry of generic versions with a price collapse. This research serves to observe the effects of the price changes and the reduction of sales and marketing efforts. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: S. Wahler, A. M üller, R. Birkemeyer Source Type: research

Delayed-onset eptifibatide-induced thrombocytopenia
CONCLUSION: This is the first published case report of profound eptifibatide-induced thrombocytopenia occurring more than 24 hours after eptifibatide initiation and serves to bring awareness that a delayed reaction can occur.PMID:37884759 | DOI:10.1093/ajhp/zxad271 (Source: American Journal of Health-System Pharmacy : AJHP)
Source: American Journal of Health-System Pharmacy : AJHP - October 26, 2023 Category: Drugs & Pharmacology Authors: Travis Huffman Evan Gleaves Glee Lenoir Rahil Rafeedheen Source Type: research

Predictors of Inappropriately Rapid Coronary Lesion Progression in Patients Undergoing Percutaneous Coronary Interventions
CONCLUSIONS: In this hypothesis-generating study, treatment with a IIb/IIIa inhibitor in the index PCI was associated with an accelerated short-term progression of some of the nontreated lesions, suggesting that this mode of anti-aggregation therapy could facilitate plaque hemorrhage and consequent acceleration of coronary atherosclerosis in eroded plaques.PMID:37876882 | PMC:PMC10591123 | DOI:10.1016/j.cjco.2023.07.002 (Source: Atherosclerosis)
Source: Atherosclerosis - October 25, 2023 Category: Cardiology Authors: Gal Sella Ortal Tuvali Michael Welt Igor Volodarsky Mustafa Jaber Haitham Abu Khadija David Koren Dan Haberman Lion Poles Alex Blatt Michael Jonas Oscar H Kracoff Gera Gandelman Jacob George Source Type: research

Single-antiplatelet regimen in ruptured cerebral blood blister and dissecting aneurysms treated with flow-diverter stent reconstruction
Conclusions Peri-interventional single-antiplatelet therapy with eptifibatide followed by prasugrel was sufficient to prevent thromboembolic events and reduce re-bleeding using an anti-thrombogenic FDS. FDS with single-antiplatelet therapy might be a viable option for ruptured blood blister and dissecting cerebral aneurysms. (Source: Journal of NeuroInterventional Surgery)
Source: Journal of NeuroInterventional Surgery - September 15, 2023 Category: Neurosurgery Authors: Madjidyar, J., Keller, E., Winklhofer, S., Toth, D., Barnaure, I., Schubert, T., Thurner, P., Fierstra, J., Willms, J. F., Regli, L., Kulcsar, Z. Tags: Hemorrhagic stroke Source Type: research

P018/190 Unexpected bleeding complication during basilar artery rescue stenting - case report
ConclusionRescue stenting is an effective and efficient method for treating basilar artery occlusion resulting from significant stenosis, and bleeding complications can be managed intraoperatively without changing pharmacological antiplatelet therapy.Disclosure of InterestNothing to disclose. (Source: Journal of NeuroInterventional Surgery)
Source: Journal of NeuroInterventional Surgery - August 21, 2023 Category: Neurosurgery Authors: Knapik, M., Popiela, T. J. Tags: 4.4 CASE PROPOSAL - Complications Source Type: research

P148/154 Safety and efficacy of eptifibatide in mechanical thrombectomy complicated by intracranial atherosclerotic disease or other pathology warranting aggressive anti-platelet therapy
ConclusionEptifibatide was shown to be a safe and effective adjunct to mechanical thrombectomy complicated by UVW. Further studies are recommended.Disclosure of InterestPresenting author has/had consultancy agreements with Stryker Neurovascular, Medtronic and Microvention Terumo and served as PI for SWIFT DIRECT study at St.George’s NHS Foundation Trust, London. (Source: Journal of NeuroInterventional Surgery)
Source: Journal of NeuroInterventional Surgery - August 21, 2023 Category: Neurosurgery Authors: Leyon, J., Kaya, A., Zhang, L., Hassan, A., Taei, T. A., Redha, N., Al-Nidawai, F., Abdulla, F. Tags: 2.3 ISCHEMIC - Treatment Source Type: research

P160/223 Acute stroke with treatment of tandem lesions under triple antiplatelet therapy: procedural saftey, stent patency and outcome at 90 days
ConclusionTL treatment under triple AP was safe in our experience, resulting in a low rate of restenosis and with favorable outcome in 92%. The influence of comorbidities on restenosis could be negligible within the described follow-up period.Disclosure of InterestPhilipp von Gottberg: Nothing to disclose.Ali Khanafer: Nothing to discloseVictoria Hellstern: Proctering for phenox GmbH.Alexandru Cimpocca: Nothing to disclose.Hans Henkes: Proctoring for phenox GmbH, Co-Founder and Co-Owner of CONTARA GmbH (Source: Journal of NeuroInterventional Surgery)
Source: Journal of NeuroInterventional Surgery - August 21, 2023 Category: Neurosurgery Authors: Philipp, V. G., Khanafer, A., Hellstern, V., Cimpoca, A., Bäzner, H., Henkes, H. Tags: 2.3 ISCHEMIC - Treatment Source Type: research

Safety and efficacy of eptifibatide in acute ischemic stroke requiring extracranial carotid artery stenting
CONCLUSIONS: Eptifibatide may have a role in the management of acute stroke requiring carotid stenting. Caution may be required in those with established infarct on presentation imaging.PMID:37574792 | DOI:10.1177/15910199231193928 (Source: Interventional Neuroradiology)
Source: Interventional Neuroradiology - August 14, 2023 Category: Radiology Authors: Michael J Waters Jan Vargas Aquilla Turk Imran Chaudry Raymond D Turner Source Type: research